Treating haematological malignancies by means of satraplatin
OwnerFelix DAHM, Thilo Joachim ZANDER +2inventors
InventorsFelix DAHM, Thilo Joachim ZANDER, Christoph Robert RENNER, Gabriel Benjamin MARKSON
Life of this patent
Estimating the term…
Abstract
The present invention relates to medical uses and methods of treatment employing satraplatin. These medical uses are beneficial in treatment of cancers, particularly haematological malignancies. The invention also relates to methods of patient stratification and methods for the selection of treatment regimens, as well as to diagnostic methods and to biomarker panels.
Claims25
Satraplatin for use in the treatment of a haematological malignancy in a patient identified as likely to benefit from such treatment by analysis of a gene selected from the group consisting of:
- a gene located in the 9p21 locus (such as MTAP, CDKN2B, CDKN2A, or DMRTA1);
- BCL2;
- TULP3;
- AOC1;
- BOC;
- DDX3X;
- CRYBG3;
- SLFN5;
- ETNK2;
- BRCA2;
- USP22;
- KIAA1683;
- AP4E1;
- PAN3;
- AC073343.11.1;
- PHF2;
- KLHDC1;
- and WRN.
Satraplatin for use according to claim 8, wherein the mutation is selected from those set out in Table 1 and Table 2.
Satraplatin for use in the treatment of a haematological malignancy with a loss of the 9p21 locus.
Satraplatin for use in the treatment of a haematological malignancy with a deficiency of a gene selected from the group consisting of:
- MTAP;
- CDKN2B;
- CDKN2A;
- and DMRTA1.
Satraplatin for use in the treatment of a haematological malignancy with mutation of a gene selected from the group consisting of:
- BCL2;
- AOC1;
- BOC;
- DDX3X;
- CRYBG3;
- SLFN5;
- ETNK2;
- BRCA2;
- USP22;
- KIAA1683;
- and AP4E1.
Satraplatin for use in the treatment of a haematological malignancy with elevated expression of TULP3;
- PAN3;
- AC073343.11.1;
- PHF2;
- KLHDC1;
- BRCA2;
- or WRN.
A method of determining the likelihood of a haematological malignancy responding favourably to satraplatin treatment, the method comprising:
- analysing a cell of the haematological malignancy for a change in a gene selected from the group consisting of:
- a gene located in the 9p21 locus (such as MTAP, CDKN2B, CDKN2A, or DMRTA1);
- BCL2;
- TULP3;
- AOC1;
- BOC;
- DDX3X;
- CRYBG3;
- SLFN5;
- ETNK2;
- BRCA2;
- USP22;
- KIAA1683;
- AP4E1;
- PAN3;
- AC073343.11.1;
- PHF2;
- KLHDC1;
- and WRN;
- wherein
- identification of a change in the gene analysed indicates that the haematological malignancy is likely to respond favourably to satraplatin treatment.
A signature panel characteristic of sensitivity of a haematological malignancy to treatment with satraplatin, the panel comprising:
- loss of copy number of at least one gene selected from the group consisting of:
- MTAP;
- CDKN2B;
- CDKN2A;
- and DMRTA1;
- and/or
- a mutation of at least one gene selected from the group consisting of:
- BCL2;
- AOC1;
- BOC;
- DDX3X;
- CRYBG3;
- SLFN5;
- ETNK2;
- BRCA2;
- USP22;
- KIAA1683;
- and AP4E1;
- and/or
- elevated expression of at least one gene selected from the group consisting of:
- TULP3;
- PAN3;
- AC073343.11.1;
- PHF2;
- KLHDC1;
- BRCA2;
- and WRN.
A signature biomarker panel characteristic of sensitivity of a haematological malignancy to treatment with satraplatin, the panel comprising at least one gene mutation selected from the group set out in Table 1 and Table 2, wherein the haematological malignancy is selected from the group consisting of:
- Burkitt lymphoma;
- DLBCL;
- and ALCL ALK+.
Satraplatin for use as a second line therapy in the treatment of cancer non-responsive to immune checkpoint therapy.
Dependencies are inferred from the claim text.